Oncomed Pharmaceuticals Director Jack W. Lasersohn Purchases 1,045 Shares (OMED)
Oncomed Pharmaceuticals (NASDAQ:OMED) Director Jack W. Lasersohn purchased 1,045 shares of Oncomed Pharmaceuticals stock on the open market in a transaction that occurred on Friday, August 15th. The stock was purchased at an average cost of $17.00 per share, with a total value of $17,765.00. Following the completion of the transaction, the director now directly owns 1,045 shares of the company’s stock, valued at approximately $17,765. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded down 0.53% during mid-day trading on Thursday, hitting $18.93. 33,690 shares of the company’s stock traded hands. Oncomed Pharmaceuticals has a 1-year low of $12.07 and a 1-year high of $42.34. The stock’s 50-day moving average is $21.03 and its 200-day moving average is $26.41. The company’s market cap is $563.4 million.
Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.53) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.03) by $0.50. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $21.28 million. On average, analysts predict that Oncomed Pharmaceuticals will post $-1.35 earnings per share for the current fiscal year.
A number of research firms have recently commented on OMED. Analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 12th. They now have a $15.00 price target on the stock. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th.
OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.